345 PARK AVENUE SOUTH, NEW YORK, NY
Lexeo Therapeutics Acquires Mantle Therapeutics Inc. in Merger
Enters Into Agreement to Acquire Mantle Therapeutics and Announces Multiple New Strategic Collaborations to Expand Leadership in Friedreich Ataxia, Investor Presentation
Reports Second Quarter 2026 Financial Results and Operational Highlights
Election of Class III Directors at Lexeo Therapeutics Annual Meeting
Investor Presentation
Reports First Quarter 2026 Financial Results and Operational Highlights
Annual Report to Security Holders
Dr. Laura Sepp-Lorenzino Appointed to Lexeo Therapeutics Board
Q2
Q1
FY 2025
Q3
Amended Quarterly Report
FY 2024
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Free Writing Prospectus